Atopic neurodermatitis
Methodology & AI Transparency ⓘ
Atopic neurodermatitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code L20.81 in Skin & Dermatology, Atopic neurodermatitis requires dermoscopy or punch in Atopic neurodermatitis (L20.81: biopsy when atypical) so specialists can calibrate treatment intensity against Fasting Lipids & in Atopic neurodermatitis (L20.81: ALT (if systemic) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Atopic neurodermatitis uses ICD-10 L20.81 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Primary evaluation for Atopic neurodermatitis incorporates dermoscopy or punch in Atopic neurodermatitis (L20.81: biopsy when atypical) and symptom diary review.
- 4 Top reported side effects / signs: Key Skin & Dermatology biomarkers for Atopic neurodermatitis (L20.81): Fasting Lipids & in Atopic neurodermatitis (L20.81: ALT (if systemic) & 25-Hydroxy Vitamin D in Atopic neurodermatitis (L20.81: & hs-CRP) (25(OH)D 40–65 ng/mL (L20.81)).
Ask our AI Specialists anything about Atopic neurodermatitis
What Is Atopic neurodermatitis?
Cataloged under federal diagnostic code L20.81 in Skin & Dermatology, Atopic neurodermatitis requires dermoscopy or punch in Atopic neurodermatitis (L20.81: biopsy when atypical) so specialists can calibrate treatment intensity against Fasting Lipids & in Atopic neurodermatitis (L20.81: ALT (if systemic) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Atopic neurodermatitis (L20.81, Skin & Dermatology) reflects cutaneous immune skewing in Atopic neurodermatitis (L20.81: (Th2/IL-4/IL-13 in atopic). longitudinal control is benchmarked via Fasting Lipids & in Atopic neurodermatitis (L20.81: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Atopic neurodermatitis (L20.81): recurrent flares triggered in Atopic neurodermatitis (L20.81: by UV exposure,)
- • Secondary Atopic neurodermatitis clinical sign: persistent erythematous plaques, in Atopic neurodermatitis (L20.81: scaly patches, pruritic)
- • Symptom flares in Atopic neurodermatitis correlating with Fasting Lipids & in Atopic neurodermatitis (L20.81: ALT (if systemic) deviation outside Within baseline reference limits (L20.81)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Atopic neurodermatitis (L20.81: biopsy when atypical) evaluation (L20.81)
Atopic neurodermatitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L20.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Atopic neurodermatitis (L20.81: ALT (if systemic) | Within baseline reference limits (L20.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Atopic neurodermatitis (L20.81: & hs-CRP) | 25(OH)D 40–65 ng/mL (L20.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Atopic neurodermatitis (L20.81: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L20.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Atopic neurodermatitis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Crisaborole Eucrisa • RxCUI 1865957 | Phosphodiesterase 4 Inhibitor | 94% | $10.6774 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Atopic neurodermatitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe: What a 2,856-Participant Study Found Abrocitinib, with proper patient and dose selection, has a manageable tolerability and longer-term safety profile appropriate for long-term use in patients with moderate-to-severe AD. American journal of clinical dermatology • 2021-09-15 • Phase III Randomized Trial | N = 2,856 | 96/100 | PMID 34406619 ↗ |
| New Insights on Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults: What a 2,444-Participant Study Found In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. The Journal of dermatological treatment • 2022-02-15 • Phase III Randomized Trial | N = 2,444 | 96/100 | PMID 32347763 ↗ |
| New Insights on Immunogenicity of dupilumab in adult and children patients with: What a 2,992-Participant Study Found In patients with AD, ADAs and NAbs had minimal impact on dupilumab concentration, efficacy, and safety, except for high-titer ADAs in a small number of patients. Frontiers in immunology • 2024-01-15 • Phase III Randomized Trial | N = 2,992 | 96/100 | PMID 39588375 ↗ |
| New Insights on Upadacitinib for moderate-to-severe eczema: Stratified analysis from three: What a 2,584-Participant Study Found Upadacitinib had consistently high skin clearance rates and itch efficacy across subgroups of patients with moderate-to-severe AD through Week 16. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | N = 2,584 | 96/100 | PMID 37247226 ↗ |
| New Insights on Bilateral Association Between eczema® and hair loss: What a 233,448-Participant Study Found Based on 7 studies, there was a significant association between AD and AA when AA was the exposure factor [odds ratio, OR, = 4.537 (95% CI: 2.409-8.544)]; based on 10 studies, there was also a significant association between... Dermatitis : contact, atopic, occupational, drug • 2024-01-15 • Meta-Analysis | N = 233,448 | 94/100 | PMID 37471232 ↗ |
Atopic neurodermatitis Patient Community & “People Like Me” Threads
Filter Atopic neurodermatitis community threads and patient logs by age, biological sex, dosage, and treatment duration.